How hard is clen on your heart?

[NathanSummers]

I know you can always read the side effects but i wanted some first hand experiences.

[VWbug66]

just like any drug, depends on the usage amount and length of time, etc....

Like rick james, did tremendous amounts of coke, died from enlarged heart...and clen does what? speeds up heart rate, so do it like rick did coke.....lay 6ft under at an early age

Lesson learned, educate urself on the things ur gunna do and dont abuse the substances and use wisely

[NathanSummers]

So whats a safe dosage cycle?

[Immortal Soldier]

The effects of Clen on the health are misunderstood, it has been used in patient who have heart failure at high dosages to treat them.

Some studies


Chronic clenbuterol next term treatment improves previous termheartnext term and myocyte function in previous term heart next term failure, with and without mechanical unloading


Combined LVAD and pharmacological therapy has been proposed to favour myocardial recovery in patients with heart failure (HF). Clenbuterol (Clen), a β2 adrenoceptor agonist has been used as a part of this strategy, but its effects on unloaded myocardium in HF are unknown.

Left coronary artery ligation or sham operation (n = 8) was performed in male Lewis rats. After 4–6 weeks, mean LV ejection fraction (EF) (%) was 34.8 ± 1.2 [34] (Mean ± SEM[n]), measured by echocardiography. Heterotopic abdominal transplantation of the failing hearts into normal recipient rats was performed to induce LV unloading (UN). Recipients were treated with saline (Sal) or Clen (2 mg/kg/day) via osmotic minipumps (HF + UN + Sal or HF + UN + Clen) for 7 days. Non-transplanted HF hearts were also treated with Sal (Sham + Sal, HF + Sal) or Clen (HF + Clen).

Clen improved LV function in HF (HF + Clen, mean LVEF%: 33.8 ± 8 [8] to 52 ± 7 [8]; P < 0.001) ex-vivo LV pressure-volume relationship was assessed in all hearts during Langendorff perfusion. Clen in UN increased dP/dTmax ((mm Hg/s) at 150 μl LV volume: HF + UN + Clen 2623 ± 349 [7]; HF + UN + Sal 1605 ± 419 [7]; P < 0.05). LV myocytes were isolated from all hearts by enzymatic digestion. Sarcomere length (SL) was measured by Fourier analysis of digitised myocyte images, at 1 Hz field-stimulation. HF caused impaired sarcomere shortening (SL amplitude (μm): Sham + Sal 0.08 ± 0.01 [46]; HF + Sal 0.07 ± 0.004 [68]; P < 0.05) and relaxation (time-to-50% relaxation (ms): Sham + Sal 71 ± 6 [42]; HF + Sal 91 ± 6 [65]; P < 0.05). Clen treatment in HF increased sarcomere shortening (SL amplitude (μm): HF + Clen 0.1 ± 0.01 [69]; vs HF + Sal; P < 0.001) and relaxation (time-to-50% relaxation (ms): HF + Clen 54 ± 2 [68] vs HF + Sal; P < 0.001). Clen treatment in UN also increased sarcomere shortening (SL amplitude (μm): HF + UN + Clen 0.1 ± 0.01 [50]; HF + UN + Sal 0.07 ± 0.01 [38]; P < 0.001) and relaxation (time-to-50% relaxation (ms): HF + UN + Clen 46 ± 2 [50]; HF + UN + Sal 90 ± 6 [38]; P < 0.001).

We conclude that Clen treatment improves whole heart and myocyte function in HF and during mechanical unloading.

Effect of Clenbuterolnext term on Cardiac and Skeletal Muscle Function During Left Ventricular Assist Device Support

Background

High-dose previous term clenbuterol next term (a selective β2-adrenergic agonist) has been proposed to promote myocardial recovery during left ventricular assist device (LVAD) support, but its effects on cardiac and skeletal muscle are largely unknown.
Methods

Seven subjects with previous termheartnext term failure (5 ischemic, 2 non-ischemic) were started on oral previous termclenbuterolnext term 5 to 46 weeks post-LVAD implantation and up-titrated to daily doses of 720 μg. The following procedures were performed at baseline and after 3 months of therapy: echocardiography at reduced support (4 liters/min); cardiopulmonary exercise testing; body composition analysis; and quadriceps maximal voluntary contraction (MVC). Myocardial histologic analysis was measured at device implantation and explantation.
Results

There were no serious adverse events or arrhythmias. Creatine phosphokinase (CPK) was elevated in 4 subjects, with no clinical sequelae. No change in ejection fraction was seen. End-diastolic dimension increased significantly (4.73 ± 0.67 vs 5.24 ± 0.66; p < 0.01), despite a trend toward increased LV mass. Body weight and lean mass increased significantly (75.5 ± 17.9 vs 79.2 ± 25.1 kg, 21.1 ± 8.9 vs 23.6 ± 9.7 kg, respectively; both p < 0.05). Exercise capacity did not change, but MVC improved significantly from 37.0 ± 15.7 to 45.8 ± 20.6 kg (p < 0.05). No significant change in myocyte size or collagen deposition was seen.
Conclusions

Cardiac function did not improve in this cohort of LVAD patients treated with high-dose previous termclenbuterol. However, clenbuterolnext term therapy increased skeletal muscle mass and strength and prevented the expected decrease in myocyte size during LVAD support. Further study will clarify its potential for cardiac and skeletal muscle recovery.

[VWbug66]

Nathan,

search around and do some reading, you start out at a low dose, and then you bump it up..You can go 2 wks 2 wks off, or you can use for 4-6 weeks and use an OTC product I cant remember the name exactly..but you use it in week 3..something like that I can't remember but there is some good threads on clen..

Type in "clen faq" and read that

[azz10]

it varies with individual. i took 120mcg ed for 2weeks. no sides at all. no shakes, nothing. except slight increase in BP.